India’s Fortis Healthcare pulls out of amalgamation scheme with Fortis Malar, SRL

Fortis Healthcare Ltd on Wednesday withdrew the scheme of arrangement and amalgamation with its units Fortis Malar Hospitals Ltd and SRL Ltd, citing a delay in its completion.

The scheme could not be completed even after 19 months due to reasons beyond the company’s control, Fortis Healthcare said in a statement late on Wednesday.

Fortis Malar runs a superspeciality hospital in Chennai while SRL operates a chain of pathology clinics.

Given the headwinds in the sector and less-than-optimum performance of the diagnostics business during the period of delay, the scheme may not result in optimum value for shareholders, Fortis added.

The cash-strapped hospitals operator, which has become the target of a bidding war, earlier this month said it would look at a new round of bids from four local and international parties and fixed June 14 as the last day for the submission.

(Reporting by Vishal Sridhar in Bengaluru; Editing by Sunil Nair)

  • Related Posts

    Bee might have bared Fangs like Death for Karishma Kapoor’s Ex Hubby

    It is assumed bee bite could have triggered fatal heart attack in Sanjay Kapoor Delhi/London:  It is not a wild guess that bee sting might have caused fatal heart attack…

    FUJIFILM resolves to detect Breast Cancer early with Apollo Hospitals

    Telugu Actor Ram Charan’s Wife & Apollo Patriarch’s Scion acts as Ambassador Hyderabad:  FUJIFILM India, a leader in healthcare technology, has launched its latest CSR campaign, ‘Find It Early, Fight…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    Pharma stock jumps after receiving approval from UK’s MHRA to sell new pharma product

    Pharma stock jumps after receiving approval from UK’s MHRA to sell new pharma product

    HIV prevention drug hailed as a ‘breakthrough’ gets FDA approval

    HIV prevention drug hailed as a ‘breakthrough’ gets FDA approval

    ED raids three pharma units in Baddi, Nalagarh

    ED raids three pharma units in Baddi, Nalagarh

    Glenmark Pharma: FDA concludes inspection at US facility, issues five observations

    Glenmark Pharma: FDA concludes inspection at US facility, issues five observations